

**PARTICULARS TO APPEAR ON THE OUTER PACKAGE {Carton to contain
"DOG ONLY" symbol}**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Carprieve 100 mg Tablets for Dogs
Carprofen

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains:
Carprofen 100 mg

3. PACKAGE SIZE

Blister strips containing 10 tablets, in cartons containing either 10, 20, 30, 50, 60, 70, 100, 140, 180, 200, 250, 280, 300, 500 or 1000 tablets.

4. TARGET SPECIES

Dogs.



5. INDICATIONS

6. ROUTES OF ADMINISTRATION

Oral use.

4mg carprofen per kg bodyweight per day.

An initial dose of 4 mg carprofen per kg bodyweight per day given as a single dose or in two equally divided doses. The daily dose may be reduced, subject to clinical response.

Duration of treatment will be dependent upon the response seen. Long-term treatment should be under regular veterinary supervision.

7. WITHDRAWAL PERIODS

8. EXPIRY DATE

Exp. {mm/yyyy}

9. SPECIAL STORAGE PRECAUTIONS

Do not store above 25°C.

Protect from light.
Store in a dry place.
Keep the blister in the outer carton.

10. THE WORDS “READ THE PACKAGE LEAFLET BEFORE USE”

Read the package leaflet before use.

11. THE WORDS “FOR ANIMAL TREATMENT ONLY”

For animal treatment only.

12. THE WORDS “KEEP OUT OF THE SIGHT AND REACH OF CHILDREN”

Keep out of the sight and reach of children.

13. NAME OF THE MARKETING AUTHORISATION HOLDER

Norbrook Laboratories Limited

14. MARKETING AUTHORISATION NUMBERS

Vm 02000/4283

15. BATCH NUMBER

Lot {number}

**PARTICULARS TO APPEAR ON THE IMMEDIATE PACKAGE {Tub Expanding
Label – contains “DOG ONLY” logo}**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Carprieve 100 mg Tablets for Dogs, Carprofen

Carprofen

2. STATEMENT OF ACTIVE SUBSTANCES

Each tablet contains:

Carprofen 100 mg

3. TARGET SPECIES

Dogs.



PACKAGE SIZE

14, 30 or 100 tablets.

4. ROUTES OF ADMINISTRATION

Oral use

Read the package leaflet before use.

5. WITHDRAWAL PERIODS

6. EXPIRY DATE

Exp. {mm/yyyy}

7. SPECIAL STORAGE PRECAUTIONS

Do not store above 25°C.

Protect from light.

Store in a dry place.

8. NAME OF THE MARKETING AUTHORISATION HOLDER

Norbrook Laboratories Limited

9. BATCH NUMBER

Lot {number}

**MINIMUM PARTICULARS TO APPEAR ON SMALL IMMEDIATE PACKAGING
UNITS {Blister Label – to contain the “DOG ONLY” symbol}**

1. NAME OF THE VETERINARY MEDICINAL PRODUCT

Carprieve 100 mg Tablets for Dogs

2. QUANTITATIVE PARTICULARS OF THE ACTIVE SUBSTANCES

Each tablet contains:

Carprofen 100 mg

3. BATCH NUMBER

Lot {number}

4. EXPIRY DATE

Exp. mm/yyyy

PARTICULARS TO APPEAR ON THE PACKAGE LEAFLET:

PACKAGE LEAFLET

1. Name of the veterinary medicinal product

Carprieve 100 mg Tablets for Dogs

2. Composition

Each tablet contains:

Active substance:

Carprofen 100 mg

Excipients:

Qualitative composition of excipients and other constituents	Quantitative composition if that information is essential for proper administration of the veterinary medicinal product
Tartrazine (E102)	1.2 mg
Microcrystalline cellulose	
Lactose monohydrate	
Croscarmellose sodium	
Povidone K30	
Sodium laurilsulphate	
Magnesium stearate	

A tablet for oral administration.

A yellow circular tablet of 8 mm embossed “100” on one side and a single break-line on the other side. The tablets can be divided into halves.



3. Target species

Dogs.

4. Indications for use

Reduction of inflammation and pain caused by musculoskeletal disorders and degenerative joint disease. As a follow up to a parenteral analgesia in the management of post operative pain.

5. Contraindications

Do not use in cats.

Do not use in pregnant or lactating bitches.

Do not use in puppies less than 4 months of age.

Do not use in cases of hypersensitivity to the active substance or to any of the excipients.

Do not use in dogs suffering from cardiac, hepatic or renal disease, where there is a possibility of gastrointestinal ulceration or bleeding, or where there is evidence of a blood dyscrasia.

6. Special warnings

Special precautions for safe use in the target species:

Use in aged dogs may involve additional risk. If such use cannot be avoided, such dogs may require a reduced dosage and careful clinical management.

NSAIDs can cause inhibition of phagocytosis and hence in the treatment of inflammatory conditions associated with bacterial infection, appropriate concurrent antimicrobial therapy should be instigated.

Avoid use in any dehydrated, hypoproteinaemic, hypovolaemic or hypotensive dogs, as there is a potential risk of increased renal toxicity.

Special precautions to be taken by the person administering the veterinary medicinal product to animals:

In case of accidental ingestion, seek medical advice immediately and show the package leaflet or label to the physician. Wash hands after handling the veterinary medicinal product.

Pregnancy and lactation:

Studies in laboratory species (rats and rabbits) have shown evidence of foetotoxic effects of carprofen at doses close to the therapeutic dose.

The safety of the veterinary medicinal product has not been established during pregnancy and lactation. Do not use in pregnant or lactating bitches.

Interaction with other medicinal products and other forms of interaction:

Do not administer other NSAIDs and glucocorticoids concurrently or within 24 hours of each other. Some NSAIDs may be highly bound to plasma proteins and compete with other highly bound drugs which can lead to toxic effects.

Concurrent administration of potential nephrotoxic drugs should be avoided.

Overdose:

Do not exceed the stated dose. There is no specific antidote for carprofen overdose but general supportive therapy, as applied to clinical overdose with NSAIDs should be applied.

7. Adverse events

Target species: Dogs

Very rare (<1 animal / 10 000 animals treated, including isolated reports):	Renal disorder ¹ Hepatopathy ¹ Vomiting ² Diarrhoea ² Blood in faeces ² Appetite loss ² Lethargy ²
---	---

¹As with other NSAIDs, there is a risk of renal or idiosyncratic hepatic adverse events.

²Typical undesirable effects associated with NSAIDs that generally occur within the first week of treatment.

Reporting adverse events is important. It allows continuous safety monitoring of a product. If you notice and side effects, even those not already listed in this package leaflet, or you think that the medicine has not worked, please contact, in the first instance, your veterinarian. You can also report any adverse events to the marketing authorisation holder or the local representative of the marketing authorisation holder using the contact details at the end of this leaflet, or via your national reporting system at:

Website: <https://www.gov.uk/report-veterinary-medicine-problem/animal-reacts-medicine>

e-mail: adverse.events@vmd.gov.uk

8. Dosage for each species, routes and method of administration

Oral use.

4mg carprofen per kg bodyweight per day.

An initial dose of 4 mg carprofen per kg bodyweight per day given as a single dose or in two equally divided doses. The daily dose may be reduced, subject to clinical response.

Duration of treatment will be dependent upon the response seen. Long-term treatment should be under regular veterinary supervision.

To extend analgesic and anti-inflammatory cover post-operatively parenteral pre-operative treatment with an injectable Carprofen product may be followed with the veterinary medicinal product at 4mg/kg/day for up to 5 days.

9. Advice on correct administration

Do not exceed the stated dose.

Return any halved tablets to the original pack and use at the next administration.

Any halved tablets remaining after the last administration of the product must be discarded.

10. Withdrawal periods

Not applicable.

11. Special storage precautions

Keep out of the sight and reach of children.

Do not store above 25°C.

Protect from light.

Store in a dry place

Do not use this veterinary medicinal product after the expiry date which is stated on the carton and blister or tub after Exp. The expiry date refers to the last day of that month.

12. Special precautions for disposal

Medicines should not be disposed of via wastewater.

Use take-back schemes for the disposal of any unused veterinary medicinal product or waste materials derived thereof in accordance with local requirements and with any applicable national collection systems. These measures should help to protect the environment.

Ask your veterinary surgeon or pharmacist how to dispose of medicines no longer required.

13. Classification of veterinary medicinal products

Veterinary medicinal product subject to prescription.

14. MARKETING AUTHORISATION NUMBER AND PACK SIZES

Vm 02000/4283

The veterinary medicinal product are supplied in either:

Polypropylene Snap Secure Tubs containing 14, 30 or 100 tablets, sealed with a white Polyethylene Snap Secure Cap.

Aluminium-Aluminium blister strips of 10 tablets in cartons containing 10, 20, 30, 50, 60, 70, 100, 140, 180, 200, 250, 280, 300, 500 or 1000 tablets.

Not all pack sizes may be marketed.

15. PID LINK (Do not print heading)

[The following statement must be included where reference to the European Union Product Database is included on the product information. This statement is relevant to both UK(GB) and UK(NI) products:]

Find more product information by searching for the 'Product Information Database' on www.gov.uk.

16. Contact details

Marketing authorisation holder and contact details to report suspected adverse reactions:

Norbrook Laboratories Limited
Station Works
Camlough Road
Newry
Co. Down
BT35 6JP
Tel No.: +44 (0)28 3025 4435
E-mail: phvdept@norbrook.co.uk

Manufacturer responsible for batch release:

Norbrook Laboratories Limited
105 Armagh Road
Newry
Co. Down
Northern Ireland
BT35 6PU

17. Other information

POM-V

Approved 12 May 2026
Gavin Hall